摘要
目的探讨强肝胶囊对慢性乙型肝炎(CHB)肝纤维化的疗效。方法选择2017年7月-2019年7月广东省廉江市人民医院收治的100例CHB患者为研究对象,依据随机数字表法将其分为对照组和治疗组,每组各50例。对照组给予葡醛内酯片、复合维生素B片,治疗组给予强肝胶囊,共治疗6个月。比较两组丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、白蛋白(ALB)、凝血酶原时间(PT)、血小板衍生生长因子BB(PDGF-BB)、转化生长因子β1(TGF-β1)、基质金属蛋白酶1(MMP-1)、基质金属蛋白酶组织抑制因子1(TIMP-1),观察两组中医体质变化,记录不良反应的发生情况。结果治疗后,两组ALT、TBil水平低于治疗前,PT短于治疗前,ALB水平高于治疗前(均P<0.05)。治疗后,两组ALT、TBil、ALB、PT比较,差异无统计学意义(P>0.05)。治疗后,对照组PDGF-BB、TGF-β1、MMP-1、TIMP-1水平与治疗前比较,差异无统计学意义(P>0.05);治疗组PDGF-BB、TGF-β1、TIMP-1水平低于治疗前,MMP-1水平高于治疗前(均P<0.05)。治疗后,治疗组PDGF-BB、TGF-β1、TIMP-1水平低于对照组,MMP-1水平高于对照组(均P<0.05)。治疗后,对照组体质变化与治疗前比较,差异无统计学意义(P>0.05);治疗组体质变化与治疗前比较,差异有统计学意义(P<0.05)。治疗后,两组体质变化比较,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论强肝胶囊能有效改善CHB患者肝纤维化指标及中医体质。
Objective To investigate the curative efficacy of Qianggan Capsules in the treatment of chronic hepatitis B(CHB)patients with hepatic fibrosis.Methods From July 2017 to July 2019,100 patients with CHB admitted to Lianjiang People’s Hospital of Guangdong Province were selected as the research subjects.According to the random number table method,they were divided into control group and treatment group,with 50 cases in each group.Control group was treated with Glucurone Tablets and Compound Vitamin B Tablets,and study group was treated with Qianggan Capsules,all treated for six months.Alanine aminotransferase(ALT),total bilirubin(TBil),albumin(ALB),prothrombin time(PT),platelet derived growth factor BB(PDGF-BB),transforming growth factorβ1(TGF-β1),matrix metalloproteinase 1(MMP-1),tissue inhibitor of matrix metalloproteinase 1(TIMP-1)were compared between two groups.The change of constitution of traditional Chinese medicine in two groups were observed and the occurrence of adverse reactions was recorded.Results After treatment,ALT and TBil levels were lower than those before treatment,PT was shorter than that before treatment,and ALB level was higher than that before treatment(all P<0.05).After treatment,there were no significant differences in ALT,TBil,ALB and PT between two groups(P>0.05).After treatment,PDGF-BB,TGF-β1,MMP-1 and TIMP-1 levels in control group were not significantly differences from those before treatment(P>0.05).PDGF-BB,TGF-β1 and TIMP-1 levels in treatment group were lower than before treatment,and MMP-1 level was higher than that before treatment.After treatment,PDGF-BB,TGF-β1 and TIMP-1 levels in treatment group were lower than those in control group,and MMP-1 level was higher than those in control group(all P<0.05).After treatment,there was no significant difference in the change of constitution between control group and that before treatment(P>0.05);there was statistical significance in the change of constitution in treatment group compared with that before treatment(P<0.05).After trea
作者
王华
杨柳明
黄玲
信洪武
赵延龙
许俊考
黄春荣
冯广贵
WANG Hua;YANG Liuming;HUANG Ling;XIN Hongwu;ZHAO Yanlong;XU Junkao;HUANG Chunrong;FENG Guanggui(Department of Traditional Chinese Medicine,Lianjiang People’s Hospital,Guangdong Province,Lianjiang524400,China;Medical School,Changjiang University,Hubei Province,Jinzhou434023,China)
出处
《中国医药导报》
CAS
2021年第10期80-83,共4页
China Medical Herald
基金
广东省中医药局科研项目(20182178)。
关键词
强肝胶囊
慢性乙型肝炎
肝纤维化
中医体质
Qianggan Capsules
Chronic hepatitis B
Hepatic fibrosis
Constitution of traditional Chinese medicine
